Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Arcus Biosciences Q1 2024 GAAP EPS $(0.05) Beats $(0.98) Estimate, Sales $145.000M Beat $33.862M Estimate

Author: Benzinga Newsdesk | May 08, 2024 05:31pm
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.98) by 94.9 percent. This is a 95.41 percent increase over losses of $(1.09) per share from the same period last year. The company reported quarterly sales of $145.000 million which beat the analyst consensus estimate of $33.862 million by 328.20 percent. This is a 480.00 percent increase over sales of $25.000 million the same period last year.

Posted In: RCUS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist